May 11, 2017 — Biotronik announced U.S. Food and Drug Administration (FDA) approval of the company's MultiPole Pacing (MPP) technology, providing physicians with additional treatment options for heart failure patients who have been non-responsive to cardiac resynchronization therapy (CRT). MPP will be available on new Biotronik CRT defibrillator (CRT-D) systems for patients with heart failure.

A large nuclear cardiology laboratory in Missouri has slashed its average radiation dose by 60 percent in eight years, according to new research presented at ICNC 2017, May 7-9 in Vienna, Austria and published in JACC: Cardiovascular Imaging.1,2 The study in over 18,000 patients showed dose reductions were achieved despite a large number of obese patients.

McKesson Imaging & Workflow Solutions, an industry leader in providing healthcare IT and imaging solutions, is pleased to announce that independent research firm KLAS has named McKesson Radiology a Category Leader in the 2017 Best in KLAS: Software & Services report for the Picture Archiving and Communications Solutions (PACS) (Community Hospital) segment, ranking number-one in the market segment. 

Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier for physicians to more effectively treat atrial fibrillation (AF). When integrated with Abbott's EnSite Precision cardiac mapping system, physicians are able to utilize dual impedance and magnetic technologies to help more precisely model the heart. This integrated system also helps physicians determine where to apply optimal contact force (pressure) when creating a lesion during a cardiac ablation to correct a heart rhythm abnormality. The Sensor Enabled technology allows physicians to create a more detailed heart model during ablation procedures than a catheter without a sensor.

Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm management (CRM) devices with technology that automatically recognizes when a patient enters a magnetic resonance imaging (MRI) environment.

Biotronik announced U.S. Food and Drug Administration (FDA) approval and the launch of Sentus ProMRI, the thinnest quadripolar left ventricular lead available in the United States. This introduction completes Biotronik's second-generation ProMRI lead portfolio, which also includes Solia ProMRI and Plexa ProMRI.

May 9, 2017 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific’s Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The approval includes new features in the Resonate devices including SmartCRT technology with multisite pacing capability for multi-electrode pacing, and compatibility with the HeartLogic Heart Failure Diagnostic Service to help physicians improve heart failure (HF) management.

May 9, 2017 — The first patient has been enrolled in the U.S. Food and Drug Administration (FDA) approved prospective feasibility study, STEMI Door-to-Unloading (DTU) with Abiomed Impella CP percutaneous ventricular assist (pVAD) system in acute myocardial infarction.

May 9, 2017 — A manuscript by physicians from Mayo Clinic and Harvard Brigham & Women's Hospital entitled, “Initial Experience with the BioSig Pure EP Signal Recording System: An Animal Laboratory Experience,” was published in The Journal of Innovations in Cardiac Rhythm Management (JICRM), April 2017 issue. Read the article by clicking here.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now